Novel Tumor Therapies

Thursday, April 16, 2026

9:45 AM - 11:15 AM US ET

Location: 157

Moderator(s)

9:45 AM - 10:00 AM US ET

Antibody-Drug Conjugates (ADCs) as Adaptors for Universal CAR T cells
Author: Elisa Ruffo, PhD (she/her/hers) – Univ. of Pittsburgh Sch. of Med.
10:00 AM - 10:15 AM US ET

Decoding Histone-DNA Methylation Crosstalk in Exhausted T Cells to Enhance Immunotherapy
Author: Hazem E. Ghoneim, PhD – Ohio State Univ. Col. of Med.
10:15 AM - 10:30 AM US ET

mRNA Vaccines Enhance Tumor Control and Synergize with 4-1BB Costimulatory Therapy
Author: Tanushree Dangi, PhD (she/her/hers) – Beth Israel Deaconess Medical Center, Harvard Medical School
10:30 AM - 10:45 AM US ET

In situ Transglutaminase 2-mediated Crosslinking of Engineered IL-7 to the Tumor Matrix Enhances Immunotherapy and Anti-PD-1 Response
Author: Angie Chun, PhD (she/her/hers) – New York University
10:45 AM - 11:00 AM US ET

Intratumoral administration of a single dose of the HEPLISAV-B Vaccine and IL-15 complexes induces tumor regression in Triple Negative Brest Cancer
Author: Malia E. Leifheit, MS, BS (she/her/hers) – Rush Univ.
11:00 AM - 11:15 AM US ET

Prime-Target neoantigen vaccination strategy enhances neoantigen-specific T cell immunity at the tumor microenvironment in murine cold tumor models
Author: Kou Hioki, PhD (he/him/his) – Erasmus University Medical Center